Efficacy and tolerability of Entecavir for hepatitis B virus infection after hematopoietic stem cell transplantation

SpringerPlus

Volumn 3, Issue 1, 2014, Pages

  Aoki, Jun ^a   Kimura, Kiminori ^a   Kakihana, Kazuhiko ^a   Ohashi, Kazuteru ^a   Sakamaki, Hisashi ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Entecavir; Hematopoietic stem cell transplantation; Hepatitis B virus

Indexed keywords

EID: 84922465506     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-450     Document Type: Article

References (20)

1. Aritomi T, Yatsuhashi H, Fujino T, Yamasaki K, Inoue O, Koga M, Kato Y, Yano M: Association of mutations in the core promoter and precore region of hepatitis virus with fulminant and severe acute hepatitis in Japan.J Gastroenterol Hepatol 1998, 13:1125–1132.
2. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.N Engl J Med 2006, 354:1001–1010.
3. Christopeit M, Weber T, Abendroth J, Dollinger M, Lubbert C, Oehme A, Kekule AS, Behre G: HBs seroconversion in a patient with acute hepatitis B treated with entecavir during immunosuppression against severe bronchiolitis obliterans in the course of chronic graft versus host disease.J Clin Virol 2010, 48:218–219.
4. Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, Dai WC, Chan AC, Cheung TT, Tsang S, Lam B, Lai CL, Lo CM: Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.Gastroenterology 2011, 141:1212–1219.
5. Giaccone L, Festuccia M, Marengo A, Resta I, Sorasio R, Pittaluga F, Fiore F, Boccadoro M, Rizzetto M, Bruno B, Marzano A: Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.Biol Blood Marrow Transplant 2010, 16:809–817.
6. Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM: Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation.Biol Blood Marrow Transplant 2009, 15:1049–1059.
7. Hsiao LT, Chiou TJ, Liu JH, Chu CJ, Lin YC, Chao TC, Wang WS, Yen CC, Yang MH, Tzeng CH, Chen PM: Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.Biol Blood Marrow Transplant 2006, 12:84–94.
8. Hui CK, Lie A, Au WY, Leung YH, Ma SY, Cheung WW, Zhang HY, Chim CS, Kwong YL, Liang R, Lau GK: A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation.Blood 2005, 106:464–469.
9. Knoll A, Boehm S, Hahn J, Holler E, Jilg W: Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation.Bone Marrow Transplant 2004, 33:925–929.
10. Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, Dehertogh D: Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.Gastroenterology 2002, 123:1831–1838.
11. Liang R, Lau GK, Kwong YL: Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem.J Clin Oncol 1999, 17:394–398.
12. Lo CM, Cheung ST, Lai CL, Liu CL, Ng IO, Yuen MF, Fan ST, Wong J: Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis.Ann Surg 2001, 233:276–281.
13. Milazzo L, Corbellino M, Foschi A, Micheli V, Dodero A, Mazzocchi A, Montefusco V, Zehender G, Antinori S: Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy.Transpl Infect Dis 2012,14(1):95–8.
14. Mutimer D, Dusheiko G, Barrett C, Grellier L, Ahmed M, Anschuetz G, Burroughs A, Hubscher S, Dhillon AP, Rolles K, Elias E: Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up.Transplantation 2000, 70:809–815.
15. Orito E, Ichida T, Sakugawa H, Sata M, Horiike N, Hino K, Okita K, Okanoue T, Iino S, Tanaka E, Suzuki K, Watanabe H, Hige S, Mizokami M: Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan.Hepatology 2001, 34:590–594.
16. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, Dienstag J, Adams P, Dickson R, Anschuetz G, Bell S, Condreay L, Brown N: A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.Hepatology 2001, 33:424–432.
17. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ: Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy.Hepatology 2009, 49:1503–1514.
18. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ: Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.Biol Blood Marrow Transplant 2009, 15:1143–1238.
19. Xi ZF, Xia Q, Zhang JJ, Chen XS, Han LZ, Wang X, Shen CH, Luo Y, Xin TY, Wang SY, Qiu de K: The role of entecavir in preventing hepatitis B recurrence after liver transplantation.J Dig Dis 2009, 10:321–327.
20. Xunrong L, Yan AW, Liang R, Lau GK: Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy–pathogenesis and management.Rev Med Virol 2001, 11:287–299.